BACKGROUND: Alzheimer's disease (AD) is the most common cause of neurodegenerative dementia in the elderly population. Scientific research is very active in the challenge of designing automated approaches to achieve an early and certain diagnosis. Re...
Alzheimer's disease (AD) has been not only a substantial financial burden to the health care system but also an emotional burden to patients and their families. Making accurate diagnosis of AD based on brain magnetic resonance imaging (MRI) is becomi...
Journal of the American Medical Directors Association
Sep 30, 2017
OBJECTIVES: This scoping study is the first step of a multiphase, international project aimed at designing a homecare robot that can provide functional support, track physical and psychological well-being, and deliver therapeutic intervention specifi...
Computer methods and programs in biomedicine
Sep 20, 2017
BACKGROUND AND OBJECTIVES: A huge number of solutions based on computational systems have been recently developed for the classification of cognitive abnormalities in older people, so that individuals at high risk of developing neurodegenerative dise...
Utilizing [18F]-AV-1451 tau positron emission tomography (PET) as an Alzheimer disease (AD) biomarker will require identification of brain regions that are most important in detecting elevated tau pathology in preclinical AD. Here, we utilized an uns...
BMC medical informatics and decision making
Jul 19, 2017
BACKGROUND: Predicting progression from a stage of Mild Cognitive Impairment to dementia is a major pursuit in current research. It is broadly accepted that cognition declines with a continuum between MCI and dementia. As such, cohorts of MCI patient...
Computer methods and programs in biomedicine
Jul 18, 2017
BACKGROUND AND OBJECTIVE: The differentiation of mild cognitive impairment (MCI), which is the prodromal stage of Alzheimer's disease (AD), from normal control (NC) is important as the recent research emphasis on early pre-clinical stage for possible...
Identifying individuals destined to develop Alzheimer's dementia within time frames acceptable for clinical trials constitutes an important challenge to design studies to test emerging disease-modifying therapies. Although amyloid-β protein is the co...
Neuroimaging has made it possible to measure pathological brain changes associated with Alzheimer's disease (AD) in vivo. Over the past decade, these measures have been increasingly integrated into imaging signatures of AD by means of classification ...
There is growing interest in the potential of neuroimaging to help develop non-invasive biomarkers in neurodegenerative diseases. In this study, connection-wise patterns of functional connectivity were used to distinguish Parkinson's disease patients...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.